Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PERSPECTIVE: Pomalidomide, Dexamethasone, and Cyclophosphamide in Relapsed/Refractory Multiple Myeloma
NCT02046915Phase 2Completed
- Sponsor
- University Hospital Tübingen
- Start
- Apr 2014
- Primary completion
- Aug 2016
- Modality
- Molecular Glues
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pomalidomide in multiple myeloma (MM), sponsored by University Hospital Tübingen. Primary endpoint: Overall Response Rate at 2 years. Started Apr 2014; status: completed.
02
Drugs
pomalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02046915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02046915.